| Autor: |
Cunningham TJ, Daut D, Wolfgang PE, Mellyn M, Maciolek S, Sponzo RW, Horton J |
| Jazyk: |
angličtina |
| Zdroj: |
Cancer [Cancer] 1976 Apr; Vol. 37 (4), pp. 1696-1700. |
| DOI: |
10.1002/1097-0142(197604)37:4<1696::aid-cncr2820370413>3.0.co;2-9 |
| Abstrakt: |
Delayed cutaneous hypersensitivity reactions to DNCB were performed before therapy in 84 patients with recurrent breast cancer. Following sensitization, a 100 microgram challenge dose was graded as a strong, weak, or negative reaction. Thirty six patients were rechallenged greater than or equal to 6 months with 109 microgram of DNCB. Patients with a strong delayed cutaneous hypersensitivity reaction to DNCB were characteried by: a significantly higher probability of surviving at 52 and 78 weeks, a longer median length of survival (strong 78 weeks, weak 43 weeks, and negative 35 weeks), and a greater probability of responding to therapy (strong 52%, weak 29%, and negative 23%). It is suggested that patients with histologic grade III tumors with a dense lymphocyte infiltrate had more frequent strong delayed cutaneous hypersensitivity reactions to DNCB than those with few lymphocytes. The correlation of DNCB skin testing with a good prognosis in this group of patients with breast cancer suggests a protective role by the immunologic defense mechanisms and warrants its further evaluation and use in the development of new therapeutic modalities. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Plný text